Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAPR inhibitor and immune checkpoint inhibitor effects in endometrial cancer organoids
jRCT1040260037Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Countries
- 1
01
Overview
Trial in endometrial cancer (EC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Organoid viability and nucleic acid levels after PARP inhibitor treatment and Gene expression changes in organoids and T cells with PARP plus immune checkpoint inhibitors. Planned start Aug 2026; status: not yet recruiting.
02
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on jRCT1040260037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1040260037.